| News Title | Agency / India Role | Key Facts |
|---|---|---|
| World's First Phase-II Nipah Vaccine Trial Begins (Bangladesh, Dec 2025) | CEPI + University of Oxford + icddr,b Bangladesh + Serum Institute of India (SII) | • World's first Phase-II Nipah vaccine trial launched in Bangladesh • Vaccine: ChAdOx1 NipahB • India Contribution: Serum Institute of India manufacturing reserve doses • CEPI funding and WHO priority pathogen support • Nipah mortality: 40–75% (CEPI) |
| World's Largest Nipah Vaccine Reserve Created | CEPI + Serum Institute of India + Oxford | • Up to 100,000 emergency vaccine doses planned • First global stockpile concept for Nipah • Designed for emergency deployment during outbreaks • Major role for Indian vaccine manufacturing sector • Supports pandemic preparedness (CEPI) |
| PHV02 Nipah Vaccine Advances to Mid-Stage Human Trials | CEPI + Public Health Vaccines (PHV) | • Candidate: PHV02 • Single-dose vaccine platform • Uses recombinant VSV technology • Among world's most advanced Nipah vaccine programmes • WHO lists Nipah among priority epidemic threats (CEPI) |
| Ethiopia Reports First-Ever Marburg Virus Outbreak (2025) | WHO + Ethiopia Ministry of Health + Sabin Vaccine Institute | • First Marburg outbreak in Ethiopian history • 14 confirmed cases, 9 deaths • WHO led surveillance, diagnostics and outbreak control • Investigational Marburg vaccine doses deployed • Outbreak officially ended Jan 2026 (World Health Organization) |
| First Human Trial of New Marburg Vaccine Starts (2026) | IAVI (International AIDS Vaccine Initiative) | • Phase-I trial started in USA • One-dose Marburg vaccine candidate • Targets Ebola-like hemorrhagic fever virus • Important because no licensed Marburg vaccine exists • Supported by global epidemic preparedness efforts (IAVI) |
| IXCHIQ – World's First Licensed Chikungunya Vaccine | FDA, EMA, MHRA, Health Canada | • First approved vaccine against Chikungunya globally • Developed by Valneva • Live-attenuated vaccine platform • Approved in USA, UK, EU, Canada • Major breakthrough against Aedes mosquito-borne disease (U.S. Food and Drug Administration) |
| Brazil Becomes First Endemic Country to License Chikungunya Vaccine | Brazil Health Authorities | • Historic because Brazil faces recurring outbreaks • First endemic country to approve vaccine use • Important model for tropical countries including India • Helps outbreak response strategy planning (PMC) |
| Second Chikungunya Vaccine (VIMKUNYA) Approved | US FDA | • Developed by Bavarian Nordic • Approved Feb 2025 • Virus-Like Particle (VLP) technology • Safer alternative to live-virus vaccine • Neutralizing antibodies in nearly 98% recipients (Bavarian Nordic) |
| Global Safety Review of First Chikungunya Vaccine | FDA + EMA | • Safety concerns emerged in elderly populations • FDA suspended distribution in USA during review • EMA restricted use in older adults • Important example of post-marketing vaccine surveillance (U.S. Food and Drug Administration) |
| First Drug That Delays Type-1 Diabetes Progression | NHS England + UK Regulators | • Drug: Teplizumab (Tzield) • First medicine to delay onset of Type-1 Diabetes • Targets autoimmune attack on pancreatic beta cells • New era in disease prevention instead of treatment • Immunotherapy breakthrough (European Medicines Agency (EMA)) |
| Disease | India's Contribution | Institution |
|---|---|---|
| Nipah | Manufacturing emergency vaccine reserve | Serum Institute of India |
| COVID-19 | Largest vaccine supplier under Vaccine Maitri | Government of India |
| Malaria | Large-scale production support for R21/Matrix-M | Serum Institute of India |
| Chikungunya | Potential future manufacturing and endemic-country relevance | Indian biotech ecosystem |
| Marburg | Indian surveillance and One Health research collaborations through ICMR monitoring networks | Indian Council of Medical Research |
| Pathogen | Vaccine Status |
|---|---|
| Nipah Virus | Phase-II trial underway |
| Marburg Virus | No licensed vaccine yet |
| Ebola Virus | Licensed vaccine available |
| Disease X | Unknown future pathogen |
| Lassa Fever | Vaccine under development |
| Crimean-Congo Hemorrhagic Fever | Vaccine research ongoing |
| Mpox | Vaccines available in some countries |
| Topic | One-Liner |
|---|---|
| Nipah Vaccine | World's first Phase-II Nipah vaccine trial launched in Bangladesh (2025). |
| India's Role | Serum Institute of India is manufacturing Nipah vaccine reserve doses. |
| Marburg | Ethiopia reported its first-ever Marburg outbreak in 2025. |
| Chikungunya | IXCHIQ became the world's first licensed Chikungunya vaccine. |
| Brazil | Brazil became the first endemic country to approve a Chikungunya vaccine. |
| Marburg Vaccine | IAVI launched first human trial of a new Marburg vaccine candidate in 2026. |
| Type-1 Diabetes | Teplizumab became the first drug to delay onset of Type-1 Diabetes. |
| Global Agency | CEPI is the leading global agency funding Nipah vaccine development. |